iBodies is a project originated at IMC, IOCB and Charles University, which is currently under a pre-seed incubation. The iBodies team focuses on development of the novel macromolecules designed to substitute antibodies in common biochemical methods. Use of such substitutes was successfully tested for wide range of laboratory methods: ELISA, flow cytometry, confocal microscopy, Western Blotting, protein immobilization and immunoprecipitation methods.
i&i Prague team supports iBodies in business development activities, including a search for potential business partners, co-developers, or iBodies-technology applications with strong market potential. During the last three years, i&i Prague helped iBodies to start multiple collaborative projects and finalized several out-licensing deals.
These synthetic antibody mimetics consist of N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer backbone decorated with low-molecular-weight functional groups: a targeting ligand, an affinity anchor and an imaging probe. In theory, iBodies can be custom designed towards any protein of interest (provided a ligand is known) and tailored based on the intended applications.
Moreover, iBodies are highly stable, easy to prepare and modify, can target via an active site which allows them to target groups of homologous proteins and many more advantages.
To discover actual products and possibilities, search https://www.ibodies.eu/.